“Authorized” Duragesic Generic Would Not “Make Sense,” Mylan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan does not anticipate an "authorized" generic for Johnson & Johnson's Duragesic (fentanyl transdermal system)
You may also be interested in...
Mylan Expects Competition From Duragesic “Authorized” Generic In January
Mylan’s guidance assumes a Jan. 24 launch of its fentanyl generic “with at least one competitor in the market.” Watson says it anticipates a 2005 launch for its generic.
Mylan Expects Competition From Duragesic “Authorized” Generic In January
Mylan’s guidance assumes a Jan. 24 launch of its fentanyl generic “with at least one competitor in the market.” Watson says it anticipates a 2005 launch for its generic.
J&J To Meet With FDA To Resolve Status Of Duragesic Generics
Johnson & Johnson will meet with FDA shortly to discuss the issues surrounding Mylan's ANDA to market a generic version of Duragesic (transdermal fentanyl)